Document is current
Any future updates will be listed below
-
Authors
Alcalde-Herraiz, Marta
Xie, JunQing https://orcid.org/0000-0002-0040-0042
Newby, Danielle
Prats, Clara https://orcid.org/0000-0002-1398-7559
Gill, Dipender https://orcid.org/0000-0001-7312-7078
Gordillo-Marañón, María https://orcid.org/0000-0003-2993-6577
Prieto-Alhambra, Daniel https://orcid.org/0000-0002-3950-6346
Català, Martí
Prats-Uribe, Albert https://orcid.org/0000-0003-1202-9153
- License Information
-
More Information
Article History
Received: 31 July 2023
Accepted: 18 October 2024
First Online: 13 November 2024
Competing interests
: DPA’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. The views expressed in this study are the personal views of MGM and do not represent the views of her current employer, the European Medicines Agency. All other authors declare no conflicts of interest.
: All participants provided informed consent to participate in each one of the GWAS we have used. UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (REC reference: 16/NW/0274). All participants provided informed consent to participate.
